Maximise product value through Medical Insights
The healthcare industry is at an inflection point with constant pressure on margins and limited opportunities to maximise asset value from highly complex technologies such as CAR-T and mRNA.
Medical Insights is emerging as a transformative organisational capability within Medical Affairs that aims to capture real-world insights through medical channels and use them to maximise product and portfolio value.
At Deallus, we believe that intelligence and insights are capabilities that are continuously evolving and remain a critical element for adapting an organisation towards upcoming market events, for building resilience, driving competitive readiness, and enhancing asset strategic planning.
Typically, Medical Insights value proposition covers:
Harnessing cross functional capabilities to generate insights through medical channels
Articulation of clinical, humanistic, and financial insights to maximise product value
Capturing real-world insights from MSL, MI, and clinical development teams
Identifying evidence gaps and assess mitigation plans during strategic planning
- Supporting evidence generation enablement and cataloging
Supplementing RWE data used within commercialisation through field insights and enhancing partnerships for evidence generation
Download to read more.
You may also be interested in…
Brain Awareness Week
Brain Awareness Week is a global campaign held every March that aims to increase public support and excitement for brain science.
Rare Diseases, Pharma’s Perennial Hitmaker
February 29th is the rarest day of the year, and this was in fact the reason why Rare Disease Day was established on this day 16 years ago by the European Organisation for Rare Diseases, commemorating the 25th anniversary of the U.S. Orphan Drug Act.
National Healthcare Security Administration (NHSA) protocols
On 4 July 2023, the National Healthcare Security Administration (NHSA) published the drafted 'Protocol for Renewal of NRDL Listed Drugs’ and ‘Negotiation Rules for Non-Exclusive Drug’. The two protocols aim to streamline the negotiation process for NRDL listed drugs and those with generic versions and are eligible for NRDL listing.
China Pharma Market Access (CPMA)
Since the establishment of the China National Medical Insurance Bureau in 2018, the goal has been to strengthen public health and medical service levels, achieve maximum utilisation of the national medical insurance fund, and to enhance the strategic purchasing capability of medical insurance funds. Significant tools in achieving this are the National Reimbursement Drug List (NRDL) and drug Volume Based Procurement (VBP), which have opened a new chapter in China’s medical reform. Meanwhile, the new drug registration process is improved, simplified, and accelerated.